OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company and other criteria. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.
For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
For KemPharm, Inc.: Gordon K. ”Rusty” Johnson 321-939-3416 [email protected] Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected]
